Sclerosis Clinical Trials

2 recruiting

Frequently Asked Questions

Common questions about Sclerosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 505 trials

Recruiting
Not Applicable

From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis

Multiple Sclerosis
Nantes University Hospital130 enrolled1 locationNCT04873492
Recruiting
Phase 1Phase 2

Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

Multiple SclerosisMultiple Sclerosis (MS) Primary ProgressiveMultiple Sclerosis (MS) Secondary Progressive+2 more
Tr1X, Inc.39 enrolled2 locationsNCT07477639
Recruiting
Phase 2

Study of COYA 302 for the Treatment of ALS

Amyotrophic Lateral Sclerosis(ALS)
Coya Therapeutics120 enrolled24 locationsNCT07161999
Recruiting
Not Applicable

Upper Limb Nerve Cryoneurolysis is Non Inferior to the Usual Care and Has Therapeutic Add Value in Dealing With Shoulder Pain and Functional Problems Caused by Spasticity and Motor Impairment

Traumatic Brain InjuryStrokeMultiple Sclerosis+5 more
Centre National de Rééducation Fonctionnelle et de Réadaptation50 enrolled1 locationNCT06782464
Recruiting
Phase 1

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting
Phase 2

A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)

Focal Segmental Glomerulosclerosis
Akebia Therapeutics60 enrolled8 locationsNCT07268638
Recruiting
Phase 4

Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

Multiple SclerosisMultiple Sclerosis (MS) - Relapsing-remitting
Northwestern University40 enrolled1 locationNCT07225361
Recruiting
Phase 4

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

Relapsing Multiple SclerosisPrimary Progressive Multiple Sclerosis
Hoffmann-La Roche60 enrolled17 locationsNCT07483450
Recruiting
Phase 2

The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis

Secondary-progressive Multiple Sclerosis (SPMS)
Cairo University46 enrolled1 locationNCT06599307
Recruiting

People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists

Multiple Sclerosis
Northwestern University100 enrolled1 locationNCT07207148
Recruiting
Phase 3

Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

Multiple Sclerosis
Sanofi160 enrolled9 locationsNCT07325292
Recruiting
Not Applicable

Effect of Multimodal Exercise Training in Patients With Multiple Sclerosis

Multiple Sclerosis
Istanbul University - Cerrahpasa40 enrolled2 locationsNCT06676618
Recruiting

Common and Specific Information From Neuroimaging and Smartphone

Multiple Sclerosis
Nantes University Hospital100 enrolled1 locationNCT05482906
Recruiting
Not Applicable

Innovative Approaches to Enhance Balance and Neuroplasticity in Multiple Sclerosis

Mobility LimitationMultiple SclerosisBalance; Distorted+1 more
University Health Network, Toronto24 enrolled1 locationNCT07174973
Recruiting
Not Applicable

Factorial Optimization Trial to Test Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue

Multiple Sclerosis
University of Washington112 enrolled1 locationNCT06809192
Recruiting
Not Applicable

Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease

Myasthenia GravisAmyotrophic Lateral SclerosisNeuromuscular Diseases (NMD)+15 more
University of Missouri-Columbia50 enrolled1 locationNCT07478172
Recruiting

Longitudinal Assessment of Iron Rims in MS Lesions

Multiple Sclerosis
Nottingham University Hospitals NHS Trust100 enrolled1 locationNCT05123443
Recruiting
Phase 1Phase 2

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

Multiple Sclerosis (MS)Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Primary Progressive+4 more
University of California, San Francisco74 enrolled1 locationNCT05359653
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Secondary-progressive Multiple Sclerosis (SPMS)
Novartis Pharmaceuticals1,275 enrolled37 locationsNCT07225504
Recruiting
Not Applicable

Autoimmune Intervention Mastery Course Study

Multiple SclerosisClinically Isolated SyndromeFibromyalgia+2 more
Terry L. Wahls400 enrolled1 locationNCT05057676